Paradoxically, the m6A methyltransferase METTL3 was reported to have dual roles in cancer (Huang et al., 2020b), acting as an oncogene in AML (Barbieri et al., 2017), breast (Niu et al., 2019), and liver cancers (Chen et al., 2018), and as a tumor suppressor in glioblastoma (Cui et al., 2017) and endometrial cancers (Liu et al., 2018). Here, METTL3 is linked to cancer.